🚀 VC round data is live in beta, check it out!
Caliway Biopharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Caliway Biopharmaceuticals and similar public comparables like Apellis Pharmaceuticals, Chongqing Zhifei, Changchun High-Tech, Sumitomo Pharma and more.
Caliway Biopharmaceuticals Overview
About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. Its pipeline candidates are CBL-514, CBA-539, and CBO-012.
Founded
2012
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$5B
Caliway Biopharmaceuticals Financials
Caliway Biopharmaceuticals reported last fiscal year revenue of $1M and negative EBITDA of ($10M).
In the same fiscal year, Caliway Biopharmaceuticals generated $840K in gross profit, ($10M) in EBITDA losses, and had net loss of ($11M).
Revenue (LTM)
Caliway Biopharmaceuticals P&L
In the most recent fiscal year, Caliway Biopharmaceuticals reported revenue of $1M and EBITDA of ($10M).
Caliway Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $840K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 70% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($10M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (844%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1859%) | XXX | XXX | XXX |
| Net Profit | ($17M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (925%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Caliway Biopharmaceuticals Stock Performance
Caliway Biopharmaceuticals has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Caliway Biopharmaceuticals' stock price is $3.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | 1.0% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCaliway Biopharmaceuticals Valuation Multiples
Caliway Biopharmaceuticals trades at 4291.4x EV/Revenue multiple, and (508.3x) EV/EBITDA.
EV / Revenue (LTM)
Caliway Biopharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Caliway Biopharmaceuticals has market cap of $5B and EV of $5B.
Equity research analysts estimate Caliway Biopharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Caliway Biopharmaceuticals has a P/E ratio of (306.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4291.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (508.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (230.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 6155.0x | XXX | XXX | XXX |
| P/E | (306.2x) | XXX | (477.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (368.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Caliway Biopharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Caliway Biopharmaceuticals Margins & Growth Rates
Caliway Biopharmaceuticals' revenue in the last fiscal year grew by 15749%.
Caliway Biopharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 15749% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (844%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (43%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 219% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1710% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1929% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Caliway Biopharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Caliway Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Apellis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Zhifei | XXX | XXX | XXX | XXX | XXX | XXX |
| Changchun High-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Sumitomo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Rovi | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caliway Biopharmaceuticals M&A Activity
Caliway Biopharmaceuticals acquired XXX companies to date.
Last acquisition by Caliway Biopharmaceuticals was on XXXXXXXX, XXXXX. Caliway Biopharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Caliway Biopharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCaliway Biopharmaceuticals Investment Activity
Caliway Biopharmaceuticals invested in XXX companies to date.
Caliway Biopharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Caliway Biopharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Caliway Biopharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Caliway Biopharmaceuticals
| When was Caliway Biopharmaceuticals founded? | Caliway Biopharmaceuticals was founded in 2012. |
| Where is Caliway Biopharmaceuticals headquartered? | Caliway Biopharmaceuticals is headquartered in Taiwan. |
| Who is the CEO of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals' CEO is Yu-Fang Ling. |
| Is Caliway Biopharmaceuticals publicly listed? | Yes, Caliway Biopharmaceuticals is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals trades under 6919 ticker. |
| When did Caliway Biopharmaceuticals go public? | Caliway Biopharmaceuticals went public in 2022. |
| Who are competitors of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals main competitors are Apellis Pharmaceuticals, Chongqing Zhifei, Changchun High-Tech, Sumitomo Pharma. |
| What is the current market cap of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals' current market cap is $5B. |
| What is the current revenue of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals' last fiscal year revenue is $1M. |
| What is the current revenue growth of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals revenue growth (vs. last FY) is 15749%. |
| What is the current EV/Revenue multiple of Caliway Biopharmaceuticals? | Current revenue multiple of Caliway Biopharmaceuticals is 4291.4x. |
| Is Caliway Biopharmaceuticals profitable? | No, Caliway Biopharmaceuticals is not profitable. |
| What is the current net income of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals' last 12 months net income is ($17M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.